Insider
Astrazeneca PLCAZN

AstraZeneca receives two regulatory approvals for its drugs

Between October 22 and October 27, 2026, AstraZeneca received two major regulatory approvals: US accelerated approval for Ultomiris and European Union approval for Enhertu. These events expand the company’s commercial portfolio in rare diseases and oncology.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
scientist using pipette with test tubes in lab
Photo by Julia Koblitz on Unsplash
43.4%
Proteinuria reduction
53%
Recurrence risk reduction
$75 million
Milestone payment

Key points

  • The US FDA granted accelerated approval—a pathway for faster approval based on surrogate endpoints—for Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN), a condition that can lead to kidney disease progression.
  • The European Union approved Enhertu for the adjuvant treatment—therapy administered after the primary treatment to prevent recurrence—of adult patients with resected HER2-positive breast cancer who have residual invasive disease.
  • The US Ultomiris approval is accelerated, requiring AstraZeneca to confirm clinical benefit in future trials for full registration.

US approval for Ultomiris.

The US FDA granted accelerated approval—a pathway for faster approval based on surrogate endpoints—for Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN), a condition that can lead to kidney disease progression. The decision relies on Phase III trial results where the drug reduced proteinuria by 43.4% compared to placebo at 34 weeks. Patients also showed a 46.6% reduction in urine protein creatinine ratio from baseline. The drug was generally well tolerated, with no new safety concerns identified.

Key clinical trial results.

Ultomiris (IgAN).
43.4%
Enhertu (breast cancer).
53%
Data from the original sources listed alongside.

European approval for Enhertu.

The European Union approved Enhertu for the adjuvant treatment—therapy administered after the primary treatment to prevent recurrence—of adult patients with resected HER2-positive breast cancer who have residual invasive disease. This decision is based on DESTINY-Breast05 trial data, showing the drug reduced the risk of recurrence or death by 53% compared to T-DM1. The approval requires AstraZeneca to make a $75 million payment to partner Daiichi Sankyo.

Risks and specifics.

The US Ultomiris approval is accelerated, requiring AstraZeneca to confirm clinical benefit in future trials for full registration. Additionally, Daiichi Sankyo, not AstraZeneca, recognizes sales of Enhertu in most EU territories.

What to watch.

For shareholders, a key event will be obtaining traditional FDA approval for Ultomiris in IgAN treatment. As the current approval is accelerated, the company intends to support it with results from ongoing Phase III trials.

Original sources

  1. 6-K filing, October 22, 2026October 22, 2026SHA-256 of our archived copy a279220d12d5…
  2. 6-K filing, October 27, 2026October 27, 2026SHA-256 of our archived copy 93cc980915b7…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards